Funder
Christian Doppler Forschungsgesellschaft
Austrian Science Fund
Publisher
Springer Science and Business Media LLC
Reference71 articles.
1. Morrow, T. & Felcone, L. H. Defining the difference: What Makes Biologics Unique. Biotechnology healthcare 1, 24–29 (2004).
2. Berlec, A. & Strukelj, B. Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells. Journal of industrial microbiology & biotechnology 40, 257–274,
https://doi.org/10.1007/s10295-013-1235-0
(2013).
3. Schiestl, M., Zabransky, M. & Sorgel, F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug design, development and therapy 11, 1509–1515,
https://doi.org/10.2147/dddt.s130318
(2017).
4. Simoens, S., Verbeken, G. & Huys, I. Biosimilars and market access: a question of comparability and costs? Targeted oncology 7, 227–231,
https://doi.org/10.1007/s11523-011-0192-7
(2012).
5. European_Medicines_Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues,
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
(2015).
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献